Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis

Endocrine-Related Cancer

Volumn 17, Issue 2, 2010, Pages 361-371

  Galland, Françoise ^a,b   Lacroix, Ludovic ^c,d   Saulnier, Patrick ^c   Dessen, Philippe ^d,e   Meduri, Geri ^a,b,i   Bernier, Michéle ^g   Gaillard, Stéphane ^h   Guibourdenche, Jean ^b,f   Fournier, Thierry ^b   Evain Brion, Daniéle ^a,b   Bidart, Jean Michel ^c,d   Chanson, Philippe ^a,b,i  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CNRS   (France)

^e Département de Génomique Fonctionnelle   (France)

^f Service de Biochimie ^*  (France)

^g FOCH HOSPITAL   (France)

^h Service de Neurochirurgie   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; MYOSIN VA; SOMATOMEDIN BINDING PROTEIN 5; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR NF E2 L1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; NONFUNCTIONING PITUITARY ADENOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MYOSIN HEAVY CHAINS; MYOSIN TYPE V; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77953548553     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0018     Document Type: Article

References (57)

1. Al-Shraim M & Asa SL 2006 The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathologica 111 1-7.
2. Asa S 2008 Practical pituitary pathology: what does the pathologist need to know? Archives of Pathology & Laboratory Medicine 132 1231-1240.
3. Asa SL, Bamberger AM, Cao B, Wong M, Parker KL & Ezzat S 1996 The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. Journal of Clinical Endocrinology and Metabolism 81 2165-2170.
4. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, Holley S, Mourtada-Maarabouni M, Williams GT, Clayton RN & Farrell WE 2004 Isolation and characterization of a novel pituitary tumor apoptosis gene. Molecular Endocrinology 18 1827-1839.
5. Du YC, Lewis BC, Hanahan D & Varmus H 2007 Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biology 5 e276.
6. Dudoit S, Fridlyand F & Speed T 2002 Comparison of discrimination methods for classification of tumors using DNA microarrays. Journal of the American Statistical Association 97 77-87.
7. Emery MN, Leontiou C, Bonner SE, Merulli C, Nanzer AM, Musat M, Galloway M, Powell M, Nikookam K, Korbonits M et al. 2006 PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clinical Endocrinology 65 389-395.
8. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS & Oyesiku NM 2001 Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. Journal of Clinical Endocrinology and Metabolism 86 3097-3107.
9. Evans CO, Reddy P, Brat DJ, O'Neill EB, Craige B, Stevens VL & Oyesiku NM 2003 Differential expression of folate receptor in pituitary adenomas. Cancer Research 63 4218-4224. (Pubitemid 36917949)
10. Ezzat S, Smyth HS, Ramyar L & Asa SL 1995 Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 80 878-884.
11. Ezzat S, Zheng L, Zhu XF, Wu GE & Asa SL 2002 Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation 109 69-78.
12. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE 2004 The prevalence of pituitary adenomas: a systematic review. Cancer 101 613-619.
13. Farrell WE 2006 Pituitary tumours: findings from whole genome analyses. Endocrine-Related Cancer 13 707-716.
14. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G & Chanson P 2006 Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology 65 536-543.
15. Gong JZ, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MBS, Hussaini IM & Laws ER 2008 Matrix metalloprotease-9, a potential biological marker in invasive pituitary adenomas. Pituitary 11 37-48.
16. Gurlek A, Karavitaki N, Ansorge O & Wass JA 2007 What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics European Journal of Endocrinology 156 143-153.
17. Hardy J 1979 Transphenoidal microsurgical treatment of pituitary tumours. In Recent Advances in the Diagnosis and Treatment of Pituitary Tumours, pp 375-388. Ed J Linfoot. New York, USA: Raven Press.
18. Heaney AP, Fernando M & Melmed S 2003 PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. Journal of Clinical Investigation 111 1381-1388.
19. Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GK et al. 2007 Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. American Journal of Pathology 170 356-365.
20. Hwa V, Oh Y & Rosenfeld RG 1997 Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3. Endocrine 6 235-242. (Pubitemid 27431393)
21. Johnson SK, Dennis RA, Barone GW, Lamps LW & Haun RS 2006 Differential expression of insulin-like growth factor binding protein-5 in pancreatic adenocarcinomas: identification using DNA microarray. Molecular Carcinogenesis 45 814-827.
22. Knapen D, Vergauwen L, Laukens K & Blust R 2009 Best practices for hybridization design in two-colour microarray analysis. Trends in Biotechnology 27 406-414.
23. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX & Grossman AB 2002 Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 87 2635-2643.
24. Lan L, Han H, Zuo H, Chen Z, Du Y, Zhao W, Gu J & Zhang Z 2010 Upregulation of myosin Va by snail is involved in cancer cell migration and metastasis. International Journal of Cancer 126 53-64.
25. Langford GM 2002 Myosin-V, a versatile motor for short-range vesicle transport. Traffic 3 859-865.
26. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J et al. 2008 The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 93 2390-2401.
27. Lundin P & Pedersen F 1992 Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography 16 519-528.
28. Meij BP, Lopes MB, Ellegala DB, Alden TD & Laws ER Jr 2002 The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. Journal of Neurosurgery 96 195-208.
29. Melmed S 2003 Mechanisms for pituitary tumorigenesis: the plastic pituitary. Journal of Clinical Investigation 112 1603-1618.
30. Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM & Oyesiku NM 2005 Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Research 65 10214-10222.
31. Morris DG, Musat M, Czirjak S, Hanzely Z, Lillington DM, Korbonits M & Grossman AB 2005 Differential gene expression in pituitary adenomas by oligonucleotide array analysis. European Journal of Endocrinology 153 143-151.
32. Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T et al. 2008 Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. Journal of Hepatology 49 207-216.
33. Pagotto U, Arzberger T, Theodoropoulou M, Grubler Y, Pantaloni C, Saeger W, Losa M, Journot L, Stalla GK & Spengler D 2000 The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Research 60 6794-6799. (Pubitemid 32059140)
34. Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, Kovacs K & Ezzat S 2004 Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. Journal of Clinical Endocrinology and Metabolism 89 1904-1911.
35. Radmacher M, McShane L & Simon R 2002 A paradigm for class prediction using gene expression profiles. Journal of Computational Biology 9 505-511.
36. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP et al. 2001 Multiclass cancer diagnosis using tumor gene expression signatures. PNAS 98 15149-15154.
37. Raslova H, Kauffmann A, Sekkai D, Ripoche H, Larbret F, Robert T, Le Roux DT, Kroemer G, Debili N, Dessen P et al. 2007 Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood 109 3225-3234.
38. Reck-Peterson SL, Provance DW Jr, Mooseker MS & Mercer JA 2000 Class V myosins. Biochimica et Biophysica Acta 1496 36-51.
39. Rodriguez OC & Cheney RE 2002 Human myosin-Vc is a novel class V myosin expressed in epithelial cells. Journal of Cell Science 115 991-1004. (Pubitemid 34257384)
40. Rudolf R, Kogel T, Kuznetsov SA, Salm T, Schlicker O, Hellwig A, Hammer JA III & Gerdes HH 2003 Myosin Va facilitates the distribution of secretory granules in the F-actin rich cortex of PC12 cells. Journal of Cell Science 116 1339-1348.
41. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV & Cusimano M 2008 Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocrine-Related Cancer 15 721-743.
42. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV & Cusimano M 2009 Ki-67 in pituitary neoplasms: a review - part I. Neurosurgery 65 429-437.
43. Salerno VP, Calliari A, Provance DW Jr, Sotelo-Silveira JR, Sotelo JR & Mercer JA 2008 Myosin-Va mediates RNA distribution in primary fibroblasts from multiple organs. Cell Motility and the Cytoskeleton 65 422-433.
44. Schneider MR, Wolf E, Hoeflich A & Lahm H 2002 IGF-binding protein-5: flexible player in the IGF system and effector on its own. Journal of Endocrinology 172 423-440.
45. Shorts-Cary L, Xu M, Ertel J, Kleinschmidt-Demasters BK, Lillehei K, Matsuoka I, Nielsen-Preiss S & Wierman ME 2007 Bone morphogenetic protein and retinoic acidinducible neural specific protein-3 is expressed in gonadotrope cell pituitary adenomas and induces proliferation, migration, and invasion. Endocrinology 148 967-975.
46. Simon R, Radmacher MD, Dobbin K & McShane LM 2003 Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. Journal of the National Cancer Institute 95 14-18. (Pubitemid 36124291)
47. Simpson DJ, Clayton RN & Farrell WE 2002 Preferential loss of death associated protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene 21 1217-1224.
48. Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, Jan M, Perrin G, Fischer G, Tabarin A et al. 2003 Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. Journal of Neurosurgery 98 1084-1093. (Pubitemid 36460901)
49. Turner HE, Nagy Z, Esiri MM, Harris AL & Wass JA 2000 Role of matrix metalloproteinase 9 in pituitary tumor behavior. Journal of Clinical Endocrinology and Metabolism 85 2931-2935.
50. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W & Liu J 2006a Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Modern Pathology 19 1149-1156.
51. Wang H, Wang H, Zhang W & Fuller GN 2006b Overexpression of IGFBP5, but not IGFBP3, correlates with the histologic grade of human diffuse glioma: a tissue microarray and immunohistochemical study. Technology in Cancer Research & Treatment 5 195-199. (Pubitemid 43946253)
52. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP & Sahin AA 2008 IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast Journal 14 261-267.
53. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D et al. 2007 A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-Related Cancer 14 887-900.
54. Wright GW & Simon RM 2003 A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19 2448-2455.
55. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD & Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 761-767.
56. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B & Klibanski A 2002 Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 87 1262-1267.
57. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR & Klibanski A 2003 A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. Journal of Clinical Endocrinology and Metabolism 88 5119-5126.